Description of Post-Immunization Adverse Events Who Received the Vaccine COVID-19 at the Tegalrejo Community Health

  • Chotijatun Nasriyah STIKES Notokusumo
  • Astri Rachmawati STIKES Notokusumo
  • Catharina Apriyani STIKES Notokusumo
  • Raden Roro Erni Kusuma Putri Universitas Safin Pati
  • Annisah Mahanani Universitas Safin Pati
Keywords: Covid-19Vaccination, ost Immunization Adverse Events

Abstract

Corona virus 19 (Covid-19) is an infectious disease caused by a new type of corona virus. The cause of this new virus was unknown before it became an outbreak in Wuhan in December 2019. One way to overcome the Covid 19 infection is by administering a vaccine. Post-Immunization Adverse Events are medical events that are thought to be related to Covid-19 vaccination. Post-Immunization Adverse Events that appear after vaccination are much milder than if infected with Covid-19 or complications caused by the virus. Not everyone who is vaccinated against Covid-19 experiences post-vaccination side events.The aim of this research is to look at the follow-up events after Covid-19 vaccination. This research method is descriptive by collecting data using a questionnaire which will be filled in by the respondent. The research sample was people who had received the second Covid-19 booster vaccine and were undergoing outpatient treatment at the internal medicine clinic at the Tegalrejo Community Health Center, Yogyakarta. The total sample taken was 100 respondents and divided into the type of IndoVac vaccine, 1 respondent (1%); Sinopharm 2 respondents (2%); Pfizer and Astra each with 21 respondents (21%); Moderna 23 respondents (23%) and Sinovac 32 respondents (32%). Of the six types of vaccines, all types of vaccines experienced side effects after immunization such as pain at the injection site. For the Moderna and Pfizer vaccine types, the most people experienced fever, namely 11 respondents for each type of vaccine. The conclusion is that almost all types of Covid-19 vaccines given by the community at the Tegalrejo Community Health Center in the second booster experienced post-immunization side events such as pain at the injection site and fever

References

Safira, M., Peranginangin, M., & Saputri, G. A. R. (2021). Evaluasi Monitoring Kejadian Ikutan Pasca Imunisasi (KIPI) Vaksin Covid-19 (Coronavac) pada Tenaga Kesehatan di Rumah Sakit Imanuel Bandar Lampung. Jurnal Mandala Pharmacon Indonesia, 7(2), 251–262.
Wilder-Smith, A., Hombach, J., Marti, M., Desai, S., & O’Brien, K. (2022). Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac. Who, March, 1–9. https://iris.paho.org/handle/10665.2/54314
Badan Pusat Statistik. (2013). No Title. https://jogjakota.bps.go.id/indicator/12/35/1/jumlah-penduduk-menurut-jenis-kelamin.html
Basuki, A. R., Mayasari, G., & Handayani, E. (2022). Gambaran Kipi (Kejadian Ikutan Pasca Imunisasi) Pada Karyawan Rumah Sakit yang Mendapatkan Imunisasi Dengan Vaksin Sinovac di RSUD Kota Yogyakarta. Majalah Farmaseutik, 18(1), 30. https://doi.org/10.22146/farmaseutik.v18i1.71908
Beijing Institute of Biological. (2021). Penjelasan Vaksin COVID-19 jenis Sinopharm. Who, 1–6.
Chemaitelly, H., AlMukdad, S., Ayoub, H. H., Altarawneh, H. N., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., … Abu-Raddad, L. J. (2022). Covid-19 Vaccine Protection among Children and Adolescents in Qatar. New England Journal of Medicine, 387(20), 1865–1876. https://doi.org/10.1056/nejmoa2210058
Chrisnawati, C., Subarjo, S., Anggraini, S., & Maratning, A. (2022). Gambaran Pengetahuan Ibu Tentang Kejadian Ikutan Pasca Imunisasi (Kipi) Dpt-Hib Di Puskesmas Asam-Asam Tahun 2021. Jurnal Keperawatan Suaka Insan (Jksi), 7(1), 1–6. https://doi.org/10.51143/jksi.v7i1.292
Hulu, V. T., Lubis, S. A., & Sri Mahyuni. (2022). Gambaran Karakteristik Kejadian Ikutan Pasca Imunisasi Vaksin Covid-19 Di Puskesmas Namorambe Tahun 2021. Jurnal Kedokteran Ibnu Nafis, 11(1), 37–48. https://doi.org/10.30743/jkin.v11i1.353
Moderna, C.-V. (2021). European Medicines Agency: EMA/15689/2021 Corr.1* Assessment report Covid-19 Vaccine Moderna. 2021.03.11, 11(March), 169. https://www.ema.europa.eu/en/documents/assessment-report/spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf
Published
2026-07-01